Full text is available at the source.
Abstract
The cardiovascular benefits of oral incretin-based therapies, such as oral semaglutide and DPP-4 inhibitors, remain less well defined.
- Injectable GLP-1 receptor agonists, like semaglutide, have shown clear cardiovascular benefits in individuals with type 2 diabetes mellitus.
- There is a need for comprehensive evaluation of the cardiovascular efficacy of oral incretin-based therapies.
- Current understanding of the cardiovascular effects of oral semaglutide and DPP-4 inhibitors is limited.
Simplified